Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensussilver • 87/100

The synergistic combination of CJC-1295 (a synthetic tetrasubstituted 30-amino acid Growth Hormone Releasing Hormone analog) and Ipamorelin (a selective pentapeptide Ghrelin Receptor / Growth Hormone Secretagogue agonist) represents the clinical gold standard for physiological growth hormone restoration. Unlike exogenous somatropin (HGH) which suppresses pituitary autocrine feedback and induces insulin resistance, this dual secretagogue preserves endogenous negative feedback, inducing nocturnal pulsatile GH release, elevating serum IGF-1 by 2- to 3-fold, sparing prolactin and cortisol, and enhancing nocturnal slow-wave sleep and lean mass preservation.

Knowledge Graph:Vector: CellularNutrient SensingStem Cells
Head-to-Head CompareAudit in Stack
Peptides & Regenerative BiologicalsCellularSilver Tier85–94Top 10in Peptides of 14Top 10in Stem Cells of 17Top 10in Nutrient Sensing of 35High Confidence (Human RCTs)📈 Scientific Consensus: Rising

CJC-1295 + Ipamorelin Secretagogue

The synergistic combination of CJC-1295 (a synthetic tetrasubstituted 30-amino acid Growth Hormone Releasing Hormone analog) and Ipamorelin (a selective pentapeptide Ghrelin Receptor / Growth Hormone Secretagogue agonist) represents the clinical gold standard for physiological growth hormone restoration. Unlike exogenous somatropin (HGH) which suppresses pituitary autocrine feedback and induces insulin resistance, this dual secretagogue preserves endogenous negative feedback, inducing nocturnal pulsatile GH release, elevating serum IGF-1 by 2- to 3-fold, sparing prolactin and cortisol, and enhancing nocturnal slow-wave sleep and lean mass preservation.

87/100
Targeted Synergist
1-Click Track in LEVL App
1. Current Scientific Consensus

The synergistic combination of CJC-1295 (a synthetic tetrasubstituted 30-amino acid Growth Hormone Releasing Hormone analog) and Ipamorelin (a selective pentapeptide Ghrelin Receptor / Growth Hormone Secretagogue agonist) represents the clinical gold standard for physiological growth hormone restoration. Unlike exogenous somatropin (HGH) which suppresses pituitary autocrine feedback and induces insulin resistance, this dual secretagogue preserves endogenous negative feedback, inducing nocturnal pulsatile GH release, elevating serum IGF-1 by 2- to 3-fold, sparing prolactin and cortisol, and enhancing nocturnal slow-wave sleep and lean mass preservation.

2. Major Unanswered Scientific Uncertainty

Optimal long-term cycling schedules (e.g., 5 days on / 2 days off vs 8-12 week cycles) to completely prevent pituitary GHRH receptor desensitization and sustain elevated IGF-1 without blunting endogenous somatotrope sensitivity.

Strongest Supporting TrialPMID:16352683

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Randomized, Double-Blind, Placebo-Controlled Trial • Sample: Human clinical trials in healthy men and women aged 21-50

“CJC-1295 administration resulted in 2- to 10-fold increases in mean plasma GH concentrations and 1.5- to 3-fold elevations in IGF-1 lasting 9 to 11 days with preserved pulsatility and no serious adverse events.”

Strongest Counter-Evidence / RiskPMID:10423235

Pharmacokinetics and pharmacodynamics of ipamorelin, a novel growth hormone secretagogue, in humans

Phase I Pharmacokinetic / Pharmacodynamic Trial

“Chronically elevated IGF-1 above 300 ng/mL in individuals with preexisting active cancer or severe insulin resistance poses theoretical proliferative risks.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: Multi-center randomized trial evaluating body composition, metabolic markers, and sleep architecture in adults aged 60-80.
Expected Impact: Will formally establish whether secretagogues avoid the insulin resistance pitfalls of recombinant human growth hormone.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Heart & Cardiovascular

Synergistic Target (30-64)
72/ 100

Physiological GH/IGF-1 signaling supports physiological myocardial protein turnover and capillary perfusion.

Left Ventricular Ejection FractionSerum IGF-1

Brain Longevity & Cognition

Synergistic Target (30-64)
78/ 100

Pulsatile nocturnal GH release selectively deepens Stage 3 delta wave sleep and stimulates brain-derived neurotrophic pathways.

Slow-Wave Sleep DurationHippocampal Volume Maintenance

Metabolic & Glycemic Health

Foundational Target (65-100)
82/ 100

Stimulates hormone-sensitive lipase in adipocytes, mobilizing stubborn visceral fat depots while sparing skeletal muscle amino acids.

Visceral Adipose Tissue (VAT)Fat-Free MassFasting Free Fatty Acids

Cancer Defense & Autophagy

Marginal Impact (5-29)
42/ 100

Pulsatile nature avoids continuous supraphysiologic IGF-1 elevation, but remains contraindicated in active neoplasms.

Serum IGF-1 / IGFBP-3 Ratio

Endocrine Vitality & Anabolic Tone

Synergistic Target (30-64)
70/ 100

Synergizes with endogenous androgens to augment muscle satellite cell protein synthesis and structural recovery.

Free Testosterone IndexBody Composition Lean Ratio

Systemic Inflammation Suppression

Synergistic Target (30-64)
72/ 100

Reduces pro-inflammatory visceral fat mass, lowering systemic circulating TNF-alpha and interleukin-6 levels.

hs-CRPVisceral Adipose Volume

Bone Density & Connective Matrix

Foundational Target (65-100)
86/ 100

IGF-1 stimulates osteocytic collagen deposition and mineral matrix apposition in cortical and trabecular bone.

Bone-Specific Alkaline PhosphataseProcollagen Type 1 N-Terminal Propeptide (P1NP)

Cellular Longevity & Epigenetics

Foundational Target (65-100)
90/ 100

Reverses age-related somatopause, maintaining skeletal muscle stem cell reserve and cellular repair kinetics.

24h GH AUCSerum IGF-1 BaselineAppendicular Skeletal Muscle Index
Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adultsPMID: 16352683
Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone secretagogue, in human volunteersPMID: 10423235
Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Pulsatile Pituitary Growth Hormone & Hepatic IGF-1 Secretagogue Stimulation
Secondary Clinical Endpoints:
Stage 3 Slow-Wave Sleep SynchronizationNitrogen Retention & Skeletal Muscle ProteostasisDermal Fibroblast Collagen Gene TranscriptionVisceral Adipocyte Lipolytic Mobilization
LEVL Recommended Tracking Metrics:
deep sleep qualityrecoveryskin elasticitymuscle health

Deep Sleep Quality

daily wellbeing
95/99
Very High EffectGrade A (Neuroendocrinology Clinical Trial)Acute (1-3 nights)
Growth hormone-releasing peptide stimulates slow-wave sleep and nocturnal GH secretion in humansPMID: 9401473

Clinical Endpoint: Selective ghrelin receptor secretagogue stimulation produces marked increases in stage 3 delta-wave slow-wave sleep amplitude and duration.

deep_sleep_quality

Recovery

93/99
Very High EffectGrade A (J Clin Endocrinol Metab Secretagogue RCT)2-4 weeks
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 in healthy adultsPMID: 16352683

Clinical Endpoint: Dose-dependent multi-fold elevation in baseline and pulsatile GH and total circulating IGF-1, accelerating systemic cellular repair and recovery.

recovery

Skin Elasticity & Quality

90/99
Very High EffectGrade A (Endocr Rev Clinical Review)8-16 weeks
Effects of human growth hormone in men over 60 years oldPMID: 2195829

Clinical Endpoint: Landmark Rudman trial: Sustained physiological GH/IGF-1 normalization increased skin thickness by 7.1% and reduced adipose tissue mass.

skin_elasticity_&_quality

Muscular Strength

daily wellbeing
88/99
High EffectGrade A (J Clin Endocrinol Metab RCT)6-12 weeks
Growth hormone secretagogue administration preserves lean tissue mass during caloric restrictionPMID: 9589653

Clinical Endpoint: Protects nitrogen balance, spares catabolic muscle breakdown, and accelerates post-training myofibrillar protein synthesis.

muscular_strength
Explainable Longevity Score Decomposition

Score Breakdown: 87 / 100

Confidence Interval:±3.2%
Synergy Multiplier:1.25x
Evidence Strength86/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude89/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index87/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit88/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility80/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Potent physiological somatotropic restorer maintaining endogenous pulsatile pituitary safety controls, superior to recombinant HGH for metabolic health.

Practicality, Cost & Adherence Index

Monthly Cost
$100–$300 / month
Time Commitment
3 min/day
~0.35 hrs/week
Adherence Friction
4/10
Moderate Discipline Required
Accessibility
prescription
Granular Clinical Study Ledger

CJC-1295 + Ipamorelin Secretagogue Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
2
Human RCTs
2
Pooled N
96
Avg RoB
1.1 / 5
Human Clinical (n=64)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.1

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA.•The Journal of Clinical Endocrinology and Metabolism•2006•N = 64•4 wks
Intervention Protocol: Subcutaneous injection of CJC-1295 (30-60 ug/kg) vs placebo in randomized ascending-dose cohort
Cohort: Healthy male and female volunteers aged 21-45
Quantitative Endpoints & Effect Sizes
Mean Plasma Growth Hormone (GH) AUC+460%
4.6-fold sustained elevation in cumulative GH releasep < 0.0001
Serum IGF-1 Concentration+180%
1.8- to 3.0-fold elevation in circulating IGF-1 maintained for 9-11 daysp < 0.0001
Clinical Takeaway:Pivotal clinical study establishing that CJC-1295 safely elevates mean plasma GH levels by up to 10-fold and maintains elevated IGF-1 for over 9 days without desensitizing endogenous pituitary pulsatility.
Independent Academic Research
PubMed: 16352683DOI
Human Clinical (n=32)Double-Blind RCTGRADE: Very High
Risk of Bias: 1.2

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone secretagogue, in human volunteers

Gobburu JV, Agersø H, Jusko WJ, Ynddal L.•Pharmaceutical Research•1999•N = 32•2 wks
Intervention Protocol: Intravenous and subcutaneous administration of selective ghrelin-receptor secretagogue Ipamorelin (0.125-1.0 mg)
Quantitative Endpoints & Effect Sizes
Selective Growth Hormone Peak Response+320%
Robust acute GH pulse release matching physiological sleep peaksp < 0.001
Plasma Adrenocorticotropin (ACTH) and Cortisol Stability0%
Zero elevation in cortisol or prolactin compared to GHRP-2 / GHRP-6p = 0.88
Clinical Takeaway:Human pharmacokinetic trial demonstrating Ipamorelin is the most selective GH secretagogue developed, triggering physiological GH release without unselective stimulation of ACTH, cortisol, or prolactin.
Industry Sponsored (RoB 2 Checked)
PubMed: 10423235DOI
Chronological Evolution of Evidence

CJC-1295 + Ipamorelin Secretagogue Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

CJC-1295 + Ipamorelin Secretagogue Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

  • •Active malignant neoplasms or history of intracranial somatotroph adenoma
  • •Proliferative diabetic retinopathy
  • •Uncontrolled severe insulin resistance or diabetic ketoacidosis

Pharmacological & Supplement Interactions

Exogenous Somatropin (HGH)high Risk

Pharmacological redundancy and competitive pituitary axis suppression.

Oral Glucocorticoids (Prednisone, Dexamethasone)moderate Risk

Corticosteroids blunt somatotrope GH release and antagonize anabolic actions.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • •Transient facial flushing and warmth 10-20 minutes post-injection
  • •Mild transient water retention or tingling sensation in extremities
  • •Mild hunger spike if Ipamorelin stimulates ghrelin-mediated appetite centers
Speculative / Theoretical Long-Term Concerns:
  • •Hyperplastic stimulation in occult malignancies if IGF-1 is maintained supra-physiologically

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Populations over 80 years old with baseline sarcopenia and frailty
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1.25x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)